Schwann Cells Trigger NF1 Pain Before Tumors Form, Mouse Study Reveals

By VirentaNews Staff — May 27, 2026

Chronic pain in neurofibromatosis type 1 (NF1) may begin long before tumors appear, according to a 2026 mouse study from Cincinnati Children’s Hospital Medical Center. Researchers found that abnormal signaling from Schwann cells—support cells in the peripheral nervous system—produces excessive levels of glial cell line–derived neurotrophic factor (GDNF), which sensitizes pain pathways. This discovery shifts the understanding of NF1, a genetic disorder affecting 1 in 3,000 people and historically associated with tumor growth, by identifying a cellular mechanism for pain that emerges independently of tumors. If confirmed in humans, the findings could lead to earlier, more effective pain treatments and reduce reliance on opioids for NF1 patients.

What causes chronic pain in NF1 before tumors develop?

For decades, chronic pain in neurofibromatosis type 1 has been assumed to result from tumors pressing on nerves or surrounding tissues. However, many patients report pain long before any tumors are detectable by imaging, a discrepancy that has puzzled clinicians. The Cincinnati Children’s team hypothesized that the root cause might lie in the function of Schwann cells, which are genetically affected in NF1 due to mutations in the NF1 gene responsible for regulating cell growth and signaling. In genetically engineered mice modeling human NF1, researchers observed that even in the absence of tumors, Schwann cells secreted abnormally high levels of GDNF—a protein known to enhance the sensitivity of sensory neurons to pain. This overproduction appears to alter neural circuits involved in pain perception, effectively turning up the volume on pain signals before any structural damage occurs.

What evidence supports Schwann cells as the source of early NF1 pain?

The study, published in Nature Neuroscience and available via nature.com, combined genetic, pharmacological, and behavioral experiments in NF1 mouse models. Using cell-specific gene deletion techniques, scientists selectively silenced the NF1 gene only in Schwann cells, leaving other cell types unaffected. These mice developed heightened pain sensitivity despite having no tumors. Further analysis revealed elevated GDNF levels in peripheral nerves, and when researchers blocked GDNF signaling using a neutralizing antibody, pain behaviors significantly decreased. Electrophysiological recordings confirmed that sensory neurons in these mice responded more vigorously to stimuli. According to lead investigator Dr. Nancy Ratner, “This is the first direct evidence that non-tumor cells can initiate pain in NF1, independent of mass lesions.” The findings align with clinical observations in NIH reports on neurofibromatosis, which note that pain is one of the most under-treated and poorly understood aspects of the condition.

Are there alternative explanations for NF1-related pain?

While the Cincinnati study presents a compelling case for Schwann cell-driven pain, some experts caution against oversimplifying a complex condition. Neurofibromatosis type 1 affects multiple cell types, including neurons, mast cells, and immune cells, all of which may contribute to pain through inflammatory or structural mechanisms. Dr. David Gutmann of Washington University’s NF Center, not involved in the study, noted that “GDNF is just one player in a larger network of pain mediators.” Additionally, psychological and central nervous system factors—such as anxiety and centralized pain syndromes common in chronic illnesses—may amplify discomfort in NF1 patients. The mouse model also has limitations: rodent pain behaviors don’t always translate directly to human subjective experience, and the genetic modifications used may not fully replicate the mosaic nature of NF1 in people. Moreover, GDNF has neuroprotective roles, so long-term suppression could have unintended consequences. These caveats suggest that while Schwann cells may initiate pain, they are likely part of a broader, multifactorial process.

What are the real-world implications for NF1 patients?

If validated in human trials, the discovery could revolutionize how pain is managed in NF1. Currently, treatment relies heavily on analgesics, including opioids, which carry risks of dependency and often provide incomplete relief. Targeting GDNF or its receptor, RET, could lead to precision therapies that prevent or reduce pain at its source. Biotech firms are already exploring monoclonal antibodies and small-molecule inhibitors for related pathways. For children with NF1—often diagnosed early through genetic testing—such interventions could be administered prophylactically, potentially preventing chronic pain from developing. The findings also underscore the need for routine pain screening in NF1 patients, even in the absence of tumors. Clinicians may soon consider biomarkers like GDNF levels in cerebrospinal fluid or peripheral blood as indicators of early neural dysfunction.

What This Means For You

For patients and families affected by neurofibromatosis type 1, this research offers hope for more effective, biologically grounded pain treatments beyond symptom management. It highlights the importance of early intervention and personalized care based on molecular mechanisms rather than visible disease markers. While human applications are still years away, the study marks a turning point in understanding NF1 as more than a tumor disorder—it’s a systemic neurological condition with complex sensory consequences.\nWhat remains unclear is whether GDNF levels correlate with pain severity in human NF1 patients, and whether blocking this pathway will be safe and effective over time. Future studies will need to validate these mechanisms in clinical cohorts and explore combination therapies that address both peripheral and central components of pain.

Source: MedicalXpress